3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Prostatic Neoplasms
2
Colonic Neoplasms
2
Triple Negative Breast Neoplasms
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Graft vs Host Disease
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Radiosurgery
10
Temozolomide
6
Magnetic Resonance Spectroscopy
6
pembrolizumab
3
Trastuzumab
3
Radiation
3
fluciclovine F-18
2
cabazitaxel
2
Surgical Procedures, Operative
2
Specimen Handling
2
Radiotherapy
2
Magnetic Resonance Imaging
2
Erlotinib Hydrochloride
2
Carboplatin
2
Bevacizumab
2
Aminolevulinic Acid
2
tucatinib
1
thymoglobulin
1
tepotinib
1
temsirolimus
1
sodium thiosulfate
1
ribociclib
1
pazopanib
1
patritumab deruxtecan
1
palbociclib
1
osimertinib
1
neratinib
1
lenvatinib
1
irinotecan sucrosofate
1
gancotamab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Brain Neoplasms
×
Atorvastatin
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn